🍽️ clopamide,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antihypertensive Effect: Clopamide belongs to the thiazide-like diuretic class of medications, which work by increasing urine production and reducing fluid volume in the body. By promoting diuresis (increased urine output), clopamide helps decrease blood volume and lower blood pressure. It acts primarily by inhibiting sodium reabsorption in the kidneys, leading to increased excretion of sodium and water. This results in decreased fluid retention and a reduction in blood pressure, thereby helping to manage hypertension.

  2. Treatment of Hypertension: Clopamide is indicated for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive medications. It is particularly effective in individuals with mild to moderate hypertension, where it can help reduce blood pressure to target levels and lower the risk of cardiovascular complications such as stroke, heart attack, and kidney disease. Clopamide is often prescribed as part of a comprehensive treatment plan that includes lifestyle modifications (such as dietary changes, exercise, and weight management) and other antihypertensive medications if necessary.

  3. Diuretic Effect: In addition to its antihypertensive properties, clopamide has diuretic effects that can help alleviate symptoms of edema (fluid retention) associated with conditions such as congestive heart failure, cirrhosis of the liver, and renal dysfunction. By increasing urine output and reducing fluid accumulation in tissues, clopamide can help improve symptoms such as swelling, shortness of breath, and fatigue in individuals with fluid overload.

  4. Electrolyte Imbalance: Like other diuretic medications, clopamide can cause electrolyte imbalances, particularly hypokalemia (low potassium levels), hyponatremia (low sodium levels), and hypomagnesemia (low magnesium levels). These electrolyte disturbances can lead to symptoms such as muscle weakness, cramps, fatigue, and cardiac arrhythmias. Patients taking clopamide should be monitored regularly for electrolyte imbalances, and supplementation may be necessary in some cases.

  5. Metabolic Effects: Clopamide may also have metabolic effects, including alterations in blood glucose levels and lipid profiles. It can increase blood glucose levels and impair glucose tolerance in some individuals, particularly those with diabetes or insulin resistance. Additionally, clopamide may affect lipid metabolism, leading to changes in cholesterol and triglyceride levels. Regular monitoring of blood glucose and lipid levels is recommended in patients taking clopamide, especially those with preexisting metabolic conditions.

  6. Contraindications and Precautions: Clopamide is contraindicated in individuals with hypersensitivity to sulfonamide-derived medications, severe renal impairment, anuria (absence of urine production), and hepatic encephalopathy. It should be used with caution in patients with electrolyte abnormalities, gout, hyperlipidemia, diabetes mellitus, and thyroid dysfunction. Clopamide may interact with other medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), lithium, corticosteroids, and certain antihypertensive agents, potentially increasing the risk of adverse effects or reducing efficacy.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of clopamide,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Akkermansia muciniphila Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Lacticaseibacillus paracasei Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by clopamide,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Clostridioides genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Akkermansia genus Decreases 📓 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Enterocloster genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Lacticaseibacillus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Bifidobacterium adolescentis species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Clostridioides difficile species Decreases 📓 Source Study Colitis
Ruminococcus bromii species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study High Levels linked to long-lived individuals
Collinsella aerofaciens species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Bacteroides ovatus species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Dorea formicigenerans species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Streptococcus parasanguinis species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Akkermansia glycaniphila species Decreases 👶 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Parabacteroides merdae species Decreases 📓 Source Study Infectious bacteria
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study

Impact of clopamide,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.5 -0.5
ADHD 4 0.2 19
Age-Related Macular Degeneration and Glaucoma 0.6 0 0
Allergic Rhinitis (Hay Fever) 0.3 2.3 -6.67
Allergies 3.7 2.3 0.61
Allergy to milk products 0.7 0.5 0.4
Alopecia (Hair Loss) 0.9 0.9
Alzheimer's disease 2 3.7 -0.85
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.4 1 1.4
Ankylosing spondylitis 2 0.8 1.5
Anorexia Nervosa 0 1.7 0
Antiphospholipid syndrome (APS) 0.2 0.2
Asthma 1 1.7 -0.7
Atherosclerosis 1.1 1.6 -0.45
Atrial fibrillation 2.5 0.7 2.57
Autism 6.2 6.3 -0.02
Barrett esophagus cancer 0.5 0.2 1.5
Biofilm 0.2 0.2
Bipolar Disorder 0.6 1.5 -1.5
Brain Trauma 0.8 0.7 0.14
Cancer (General) 0.4 3 -6.5
Carcinoma 2.7 2.3 0.17
Celiac Disease 1.2 4 -2.33
Cerebral Palsy 1.6 1.4 0.14
Chronic Fatigue Syndrome 4.9 3.4 0.44
Chronic Kidney Disease 0.6 1 -0.67
Chronic Lyme 0.7 -0.7
Chronic Obstructive Pulmonary Disease (COPD) 1.5 0.6 1.5
Chronic Urticaria (Hives) 0.8 0.7 0.14
Coagulation / Micro clot triggering bacteria 0.2 1.4 -6
Colorectal Cancer 2.5 0.8 2.13
Constipation 0.4 0.8 -1
Coronary artery disease 0.7 0.9 -0.29
COVID-19 8.7 9.9 -0.14
Crohn's Disease 3.9 3.7 0.05
cystic fibrosis 1.1 -1.1
deep vein thrombosis 1 -1
Depression 6.8 5.8 0.17
Dermatomyositis 0.2 0.5 -1.5
Eczema 0.5 1.4 -1.8
Endometriosis 1.5 1.4 0.07
Eosinophilic Esophagitis 0.5 -0.5
Epilepsy 2 2.1 -0.05
Fibromyalgia 1.6 0.8 1
Functional constipation / chronic idiopathic constipation 3 1.9 0.58
gallstone disease (gsd) 1.5 0.9 0.67
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.5 1 -1
Generalized anxiety disorder 0.4 1.8 -3.5
giant cell arteritis 0.1 -0.1
Glioblastoma 0.2 -0.2
Graves' disease 1 1.3 -0.3
Halitosis 0.7 0.2 2.5
Hashimoto's thyroiditis 2.2 0.7 2.14
Hidradenitis Suppurativa 0.2 0.5 -1.5
High Histamine/low DAO 0.8 0.8 0
hypercholesterolemia (High Cholesterol) 0.5 0.7 -0.4
hyperglycemia 0.2 2.1 -9.5
Hyperlipidemia (High Blood Fats) 1.1 0.3 2.67
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 1.9 5.1 -1.68
Hypothyroidism 1.1 -1.1
Hypoxia 0.6 0.6
IgA nephropathy (IgAN) 1.6 -1.6
Inflammatory Bowel Disease 2.5 5.6 -1.24
Insomnia 0.8 0.9 -0.13
Intelligence 0.1 0.1
Intracranial aneurysms 1 0.3 2.33
Irritable Bowel Syndrome 3.3 3.1 0.06
Liver Cirrhosis 3.5 2.7 0.3
Long COVID 4.7 7.4 -0.57
Low bone mineral density 0.6 -0.6
Lung Cancer 0.5 1.6 -2.2
Mast Cell Issues / mastitis 0.2 0.8 -3
ME/CFS with IBS 0.8 1.8 -1.25
ME/CFS without IBS 1 1.2 -0.2
Menopause 2.4 2.4
Metabolic Syndrome 4.8 6.7 -0.4
Mood Disorders 9.3 6.1 0.52
multiple chemical sensitivity [MCS] 1.6 0.4 3
Multiple Sclerosis 5.1 2 1.55
Multiple system atrophy (MSA) 2.1 1.2 0.75
neuropathic pain 2 -2
Neuropathy (all types) 1 1
neuropsychiatric disorders (PANDAS, PANS) 0.4 0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 1.2 5.3 -3.42
NonCeliac Gluten Sensitivity 2.1 0.7 2
Obesity 6.4 4.1 0.56
obsessive-compulsive disorder 4 2.5 0.6
Osteoarthritis 1 0.4 1.5
Osteoporosis 1.4 1.3 0.08
pancreatic cancer 0.6 0.6
Parkinson's Disease 4.9 3.4 0.44
Polycystic ovary syndrome 1.1 2.4 -1.18
Postural orthostatic tachycardia syndrome 0.1 0.5 -4
Premenstrual dysphoric disorder 1.2 0 0
primary biliary cholangitis 0.2 0.3 -0.5
Psoriasis 3.3 1.3 1.54
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 4 2.5 0.6
Rosacea 1 0.5 1
Schizophrenia 5.9 1.8 2.28
scoliosis 0.8 -0.8
Sjögren syndrome 2.3 2.1 0.1
Sleep Apnea 1.2 1.3 -0.08
Slow gastric motility / Gastroparesis 1 0.5 1
Small Intestinal Bacterial Overgrowth (SIBO) 0.2 1 -4
Stress / posttraumatic stress disorder 1.7 2.6 -0.53
Systemic Lupus Erythematosus 1.9 2.2 -0.16
Tic Disorder 0.7 0.9 -0.29
Tourette syndrome 0.3 0.2 0.5
Type 1 Diabetes 2.1 1.8 0.17
Type 2 Diabetes 4.7 3.8 0.24
Ulcerative colitis 1.7 3.2 -0.88
Unhealthy Ageing 2.5 1.6 0.56
Vitiligo 1.2 0.9 0.33

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [35.170.81 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [35.170.81 ]